Evidence map›Paper›PMID 29026147›Full record

ArticleScientific reports2017

Vascular Endothelial Growth Factor in Cartilage Development and Osteoarthritis.

Masashi Nagao, John L Hamilton, Ranjan Kc, Agnes D Berendsen, Xuchen Duan, Chan Wook Cheong, Xin Li, Hee-Jeong Im, Bjorn R Olsen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Developing anFrontiers in immunology · 2025
    Article
  17. Article
  18. Review
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Masashi NagaoDepartment of Developmental Biology, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA, 02115, USA. nagao@juntendo.ac.jp.
John L HamiltonDepartment of Biochemistry, Rush University Medical Center, 1735 W, Harrison Street, Chicago, IL, 60612, USA.
Ranjan KcDepartment of Biochemistry, Rush University Medical Center, 1735 W, Harrison Street, Chicago, IL, 60612, USA.
Agnes D BerendsenDepartment of Developmental Biology, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA, 02115, USA.
Xuchen DuanDepartment of Developmental Biology, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA, 02115, USA.
Chan Wook CheongDepartment of Developmental Biology, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA, 02115, USA.ORCID 0000-0003-2488-7374
Xin LiDepartment of Biochemistry, Rush University Medical Center, 1735 W, Harrison Street, Chicago, IL, 60612, USA.
Hee-Jeong ImJesse Brown Veterans Affairs (VA) Medical Center, 820S, Damen Avenue, Chicago, IL, 60612, USA. Hee-Jeong_Sampen@va.gov.
Bjorn R OlsenDepartment of Developmental Biology, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA, 02115, USA. bjorn_olsen@hms.harvard.edu.
Harvard University · USRush University Medical Center · USUniversity of Illinois Chicago · US

Funding

STRUCTURE OF TYPE I AND TYPE II PROCOLLAGENSR01AR036819 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI OLSEN, BJORN REINO · 1986 to 2016
$8.7M
Pain Mechanisms of Knee Joint OsteoarthritisR01AR062136 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI CHEN, DI · 2012 to 2016
$1.7M
BIOGENESIS OF EXTRACELLULAR MATRIXR37AR036819 · NIAMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI OLSEN, BJORN R · 1992 to 2001
$827k
Biogenesis of Extracellular MatrixR56AR036819 · NIAMS · HARVARD MEDICAL SCHOOL · PI OLSEN, BJORN REINO · 2018 to 2019
$746k
Allosteric Small Molecule Inhibitor Of Nerve Growth Factor Signaling in Low Back PainR21AR067935 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI CHEN, DI · 2015 to 2016
$375k
Anti-VEGF Therapy in Osteoarthritis and Associated PainF31AR070002 · NIAMS · RUSH UNIVERSITY MEDICAL CENTER · PI HAMILTON, JOHN L · 2016 to 2017
$84k
OSTEOARTHRITIS AND KNEE JOINT PAINI01BX002647 · VA · JESSE BROWN VA MEDICAL CENTER · PI SAMPEN, HEE-JEONG IM · 2015 to 2023
–
BLRD VA I01 BX002647NIAMS NIH HHS F31 AR070002NIAMS NIH HHS R01 AR036819NIAMS NIH HHS R01 AR062136NIAMS NIH HHS R21 AR067935NIAMS NIH HHS R37 AR036819NIAMS NIH HHS R56 AR036819
6 · The paper itself

Abstract

Genome wide studies indicate that vascular endothelial growth factor A (VEGF) is associated with osteoarthritis (OA), and increased VEGF expression correlates with increased disease severity. VEGF is also a chondrocyte survival factor during development and essential for bone formation, skeletal growth and postnatal homeostasis. This raises questions of how the important embryonic and postnatal functions of VEGF can be reconciled with an apparently destructive role in OA. Addressing these questions, we find that VEGF acts as a survival factor in growth plate chondrocytes during development but only up until a few weeks after birth in mice. It is also required for postnatal differentiation of articular chondrocytes and the timely ossification of bones in joint regions. In surgically induced knee OA in mice, a model of post-traumatic OA in humans, increased expression of VEGF is associated with catabolic processes in chondrocytes and synovial cells. Conditional knock-down of Vegf attenuates induced OA. Intra-articular anti-VEGF antibodies suppress OA progression, reduce levels of phosphorylated VEGFR2 in articular chondrocytes and synovial cells and reduce levels of phosphorylated VEGFR1 in dorsal root ganglia. Finally, oral administration of the VEGFR2 kinase inhibitor Vandetanib attenuates OA progression.

Indexed as

Administration, OralAnimalsAntibodiesBone DevelopmentCartilage, ArticularCell DifferentiationCell LineageChondrocytesCollagen Type IIDisease ProgressionEndotheliumFemaleGene DeletionGene Expression RegulationGrowth PlateIntegrasesAntibodiesCollagen Type IICre recombinaseIntegrasesProtein Kinase InhibitorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID29026147
PMCPMC5638804
OpenAlexW2763858613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.